Investor Takeaway For investors seeking exposure to the GLP-1 boom in India, the key is to identify companies with proven capabilities in: Peptide synthesis Sterile injectable manufacturing Global regulatory compliance CDMO services with US/EU clients Recommended Monitoring: R&D updates and capacity expansions Any tie-ups with global GLP-1 players Clinical trial progress for biosimilar versions Regulatory approvals (USFDA, EMA) Export data to key markets (USA, Canada, China) Conclusion The weight loss drug boom is changing global healthcare and creating a huge business opportunity for Indian pharma companies
When these two molecules sit together in solution, they can interact chemically in ways that neither the pharmacy nor the patient can see, smell, or detect without sophisticated analytical equipment
However, as clinicians celebrate these advances, a Read More Beyond the FIB-4: Why Diabetes Care Is Becoming a Hepatology-Endocrinology Partnership May 20, 2026 Articles, Diabetes, Gastroenterology, Obesity, Obesity, Type 2 Diabetes, Type 2 Diabetes 1,761 views Screening for fatty liver disease in patients with diabetes is no longer limited to identifying elevated liver enzymes or calculating a fibrosis score during an annual visit
We are confident that the expansion of Wegovy to a pill will help patients who may have not sought or accepted treatment before," said Dave Moore, Executive Vice President, US Operations at Novo Nordisk
However, non-obese participants did not experience the same level of decline
It is critically involved in a wide range of biological processes, including modulation of OS, maintenance of cellular homeostasis, immune regulation, DNA replication and damage repair, cell cycle progression, apoptosis, and aging (103)
